Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Pharmacogenomics. 2005;5(1):35-43.

Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma.

Author information

1
Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada

Abstract

Pharmacogenomic studies in multiple myeloma, a neoplasia of clonally expanded malignant bone marrow plasma cells, are helping to set the stage for individualized therapy. Although relatively few in numbers, these studies are already providing new therapeutic targets and avenues for drug discoveries as well as contributing to novel prognostic markers in multiple myeloma. High-throughput mutation screening of the kinome promises to identify further novel targets for therapy. Genetics and gene expression profiling technology have improved molecular-based patient stratification and prognostic staging, expanded knowledge of the molecular mechanism of chemotherapeutic agents, and provided a better understanding of myeloma bone disease. The use of pharmacogenomic strategies in myeloma is thus already changing medical practice.

PMID:
15727487
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center